These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 22492392)
21. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases]. Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458 [TBL] [Abstract][Full Text] [Related]
22. [Combined FDG PET/CT imaging for restaging of colorectal cancer patients: impact of image fusion on staging accuracy]. Strunk H; Bucerius J; Jaeger U; Joe A; Flacke S; Reinhardt M; Hortling N; Palmedo H Rofo; 2005 Sep; 177(9):1235-41. PubMed ID: 16123869 [TBL] [Abstract][Full Text] [Related]
23. Imaging features of colorectal liver metastasis in FDG PET-CT: a retrospective correlative analysis between CT attenuation and FDG uptake. Au-Yeung AW; Luk WH; Lo AX Nucl Med Commun; 2012 Apr; 33(4):403-7. PubMed ID: 22273638 [TBL] [Abstract][Full Text] [Related]
24. [Value of (18)F-FDG PET-CT in the preoperative N staging of non-small cell lung cancer]. Li M; Wu N; Liang Y; Zheng R; Liu Y; Zhang WJ; Zhao P Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):288-92. PubMed ID: 19615286 [TBL] [Abstract][Full Text] [Related]
25. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle. Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129 [TBL] [Abstract][Full Text] [Related]
26. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities. Salem SS; Shahin MA Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387 [TBL] [Abstract][Full Text] [Related]
27. Performance of FDG PET/CT in postoperative colorectal cancer patients with a suspected recurrence and a normal CEA level. Lee JH; Park SG; Jee KN; Park DG; Namgung H; Song IH Nucl Med Commun; 2010 Jun; 31(6):576-82. PubMed ID: 20216474 [TBL] [Abstract][Full Text] [Related]
28. Dual-time-point F-18 FDG PET/CT for evaluation in patients with malignant lymphoma. Shinya T; Fujii S; Asakura S; Taniguchi T; Yoshio K; Alafate A; Sato S; Yoshino T; Kanazawa S Ann Nucl Med; 2012 Oct; 26(8):616-21. PubMed ID: 22692457 [TBL] [Abstract][Full Text] [Related]
29. Dual time point 2-deoxy-2-[18F]fluoro-D-glucose PET/CT: nodal staging in locally advanced breast cancer. García Vicente AM; Soriano Castrejón A; Cruz Mora MÁ; Ortega Ruiperez C; Espinosa Aunión R; León Martín A; González Ageitos A; Van Gómez López O Rev Esp Med Nucl Imagen Mol; 2014; 33(1):1-5. PubMed ID: 23707190 [TBL] [Abstract][Full Text] [Related]
30. Routine (18)F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making. Kantorová I; Lipská L; Bêlohlávek O; Visokai V; Trubaĉ M; Schneiderová M J Nucl Med; 2003 Nov; 44(11):1784-8. PubMed ID: 14602860 [TBL] [Abstract][Full Text] [Related]
32. PET/CT pattern analysis for surgical staple line recurrence in patients with colorectal cancer. Shyn PB; Madan R; Wu C; Erturk SM; Silverman SG AJR Am J Roentgenol; 2010 Feb; 194(2):414-21. PubMed ID: 20093604 [TBL] [Abstract][Full Text] [Related]
33. Evaluation of dual-time-point 18F-FDG PET for staging in patients with lung cancer. Uesaka D; Demura Y; Ishizaki T; Ameshima S; Miyamori I; Sasaki M; Fujibayashi Y; Okazawa H J Nucl Med; 2008 Oct; 49(10):1606-12. PubMed ID: 18794269 [TBL] [Abstract][Full Text] [Related]
34. The added value of dual-time-point 18F-FDG PET/CT imaging in the diagnosis of colorectal cancer liver metastases. Mao W; Zhou J; Qiu L; Yin H; Tan H; Shi H Abdom Radiol (NY); 2020 Apr; 45(4):1075-1081. PubMed ID: 31927618 [TBL] [Abstract][Full Text] [Related]
35. The clinical value of dual-time point 18F-FDG PET/CT for differentiating extrahepatic cholangiocarcinoma from benign disease. Choi EK; Yoo IeR; Kim SH; O JH; Choi WH; Na SJ; Park SY Clin Nucl Med; 2013 Mar; 38(3):e106-11. PubMed ID: 23354026 [TBL] [Abstract][Full Text] [Related]
36. Limited Identification of Dual-time-point Positron Emission Tomography/Computed Tomography in Advanced Colorectal Neoplasms. Kashiwagi K; Nakazato Y; Arai M; Iwasaki E; Naganuma M; Inoue N; Iwao Y; Ogata H; Murakami K; Kanai T Intern Med; 2017; 56(11):1287-1292. PubMed ID: 28566588 [TBL] [Abstract][Full Text] [Related]
37. Incremental value of 18F-FDG PET/CT in therapeutic decision-making of potentially curable esophageal adenocarcinoma. Purandare NC; Pramesh CS; Karimundackal G; Jiwnani S; Agrawal A; Shah S; Kulkarni M; Laskar SG; Rangarajan V Nucl Med Commun; 2014 Aug; 35(8):864-9. PubMed ID: 24751701 [TBL] [Abstract][Full Text] [Related]
38. The role of (18)F-FDG PET/CT in the diagnosis of breast cancer and lymph nodes metastases and micrometastases may be limited. Zhang X; Wu F; Han P Hell J Nucl Med; 2014; 17(3):177-83. PubMed ID: 25526754 [TBL] [Abstract][Full Text] [Related]
39. The potential usefulness of (18)F-FDG PET/CT for detecting colorectal carcinoma and adenoma in asymptomatic adults. Hwang JP; Woo SK; Yoon SY; Jeong SY Ann Nucl Med; 2015 Feb; 29(2):157-63. PubMed ID: 25358843 [TBL] [Abstract][Full Text] [Related]
40. What approach should we take for the incidental finding of increased 18F-FDG uptake foci in the colon on PET/CT? Şimşek FS; İspiroğlu M; Taşdemir B; Köroğlu R; Ünal K; Özercan IH; Entok E; Kuşlu D; Karabulut K Nucl Med Commun; 2015 Dec; 36(12):1195-201. PubMed ID: 26426964 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]